Skip to main content
. 2021 May 13;6(3):504–512. doi: 10.1002/epi4.12494

TABLE 5.

Serious treatment‐emergent adverse events (>1 in any group)

Serious TEAE, n (%)

Moderate‐frequency usage

(<2 doses/month)

(n = 69)

High‐frequency usage

(2‐5 doses/month)

(n = 80)

Very‐high‐frequency usage

(>5 doses/month)

(n = 9)

Seizure 10 (14.5) 7 (8.8) 1 (11.1)
Seizure cluster 2 (2.9)
Status epilepticus 5 (6.3)
Pneumonia 4 (5.8) 3 (3.8)
Pyrexia 2 (2.5)

Abbreviation: TEAE, treatment‐emergent adverse event.